More about Krishna Institute of Medical Sciences Limited
Fundamentals for Krishna Institute of Medical Sciences Limited
Regulatory Filings for Krishna Institute of Medical Sciences Limited
Defence Profits Reach Dharavi's Machinists
From COVID Debt to Green Despair: Industrial Discharge Is Destroying India’s Last Prawn Nurseries
The Hidden Cost of India's Electronics Assembly Push: A 40% E-Waste Surge and the Death of Affordable Repair
The Wedding Loan Trap: How India’s Microfinance Boom Turned Housewives Into Ghost Borrowers and Temple Brass Into EMI Cash
Fundamentals for Krishna Institute of Medical Sciences Limited
Business Operations:
Sector: HealthcareIndustry: Medical Care Facilities
Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand name in India. The company offers range of specialties, including cardiac, dental, neuro, oncological, orthopedic, renal, reproductive, and robotic sciences, as well as gastroenterology and hepatology, heart and lung transplant, organ transplantation, mother and childcare, and pediatrics services. It focuses on accident, biochemistry, anesthesiology, bariatric surgery, andrology and infertility, arthroscopy, Alzheimer's, bone, joint center specialties, and others. In addition, the company provides medical procedures for aneurysm, ankle arthritis and total ankle replacement, anterior cervical discectomy and fusion surgery, anterior resection, aortic aneurysm, aortic stent graft, aortic valve replacement, arthroscopy, atrial septal defect, bariatric surgery, and others. Krishna Institute of Medical Sciences Limited was incorporated in 1973 and is based in Secunderabad, India.
Revenue projections:
KIMS is projected to see a decline in revenue compared to last year, which could lead to investor caution. A drop in earnings is often viewed as a negative signal for profitability, making it more difficult for the company to maintain investor confidence in its financial health.
Financial Ratios:
| currentRatio | 0.000000 |
|---|---|
| forwardPE | 51.987835 |
| debtToEquity | 123.719000 |
| earningsGrowth | -0.401000 |
| revenueGrowth | 0.292000 |
| grossMargins | 0.595950 |
| operatingMargins | 0.120480 |
| trailingEps | 7.530000 |
| forwardEps | 12.800110 |
KIMS's high forward PE suggests the stock may be overvalued, potentially limiting future price gains and increasing the risk of a price correction. Investors should consider this metric carefully alongside other fundamentals to assess the stock's true value and growth potential.
KIMS's high debt-to-equity ratio indicates significant leverage, meaning the company has more debt compared to its equity. While this can accelerate growth, it also increases financial risk if revenue or profits decline.
KIMS's low earnings and revenue growth point to a likely decrease in profits. This suggests that the company is facing financial difficulties and may struggle to maintain its current level of profitability.
With negative gross and operating margins, KIMS is facing losses at both the production and operational levels. This signals significant financial strain and may indicate that the company is struggling to manage costs effectively.
With KIMS's forward EPS higher than its trailing EPS, the company is expected to be more profitable in the current financial year. This signals confidence in KIMS's growth potential, as improved earnings are forecasted compared to the prior year's performance.
Price projections:
The stock price of KIMS has often been near the lower end of projections, indicating that it may not be meeting investor expectations. This trend could suggest challenges ahead for the company.
Recommendation changes over time:
KIMS has been receiving a buy bias from analysts, indicating confidence in its investment potential. This could drive more investors to view KIMS as a reliable choice for their money, offering a promising avenue for future growth and financial gains.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
From Lifesaving Drugs to Sick Units: The Hidden Energy Crisis Inside India’s Pharma Clusters
From Price Pressures to Profit Power: The MSME Playbook Redefining India’s Economy
₹90 Crore Bet Signals a Massive Shift in India’s Rural Economy